These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 18252172)

  • 1. [Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].
    Pedersen MØ; Pedersen DS; Pedersen M; Penkowa M
    Ugeskr Laeger; 2008 Feb; 170(6):421-6. PubMed ID: 18252172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 6. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia.
    Plested JS; Harris SL; Wright JC; Coull PA; Makepeace K; Gidney MA; Brisson JR; Richards JC; Granoff DM; Moxon ER
    J Infect Dis; 2003 Apr; 187(8):1223-34. PubMed ID: 12696001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines against meningococcal disease: current and future technologies.
    Riddell A; Buttery J
    Expert Opin Biol Ther; 2001 May; 1(3):385-99. PubMed ID: 11727513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neisseria meningitidis lipopolysaccharides in human pathology.
    Brandtzaeg P; Bjerre A; Øvstebø R; Brusletto B; Joø GB; Kierulf P
    J Endotoxin Res; 2001; 7(6):401-20. PubMed ID: 11753210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 17. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
    Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
    Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 19. History of meningococcal vaccines and their serological correlates of protection.
    Vipond C; Care R; Feavers IM
    Vaccine; 2012 May; 30 Suppl 2():B10-7. PubMed ID: 22607894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.
    Verheul AF; Snippe H; Poolman JT
    Microbiol Rev; 1993 Mar; 57(1):34-49. PubMed ID: 8464406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.